

Summary of changes to specifications for AUA AQUA measures for PY2025

Measure	Title (PY2025 version)	2024 Measure Specification	Changes made to 2025 measure specification
AQUA8	Hospital admissions or infectious complications within 30 days of prostate biopsy	N/A	No changes
AQUA14	Stones: Repeat Shock Wave Lithotripsy (SWL) Within 6 Months of Initial Treatment	N/A	No changes
AQUA15	Stones: Urinalysis or Urine Culture Performed Before Surgical Stone Procedures	N/A	No changes
AQUA16	Non-Muscle Invasive Bladder Cancer: Repeat Transurethral Resection of Bladder Tumor (TURBT) for T1 disease	N/A	No changes
AQUA26	N/A	N/A	AUA has retired this measure; it is no longer available for use in MIPS
AQUA35	Non-Muscle Invasive Bladder Cancer: Initial Management/Surveillance for Non-Muscle Invasive Bladder Cancer	N/A	No changes
AQUA36	Prostate Cancer: Confirmation Biopsy in Newly Diagnosed Patients on Active Surveillance	Description: Percentage of newly diagnosed low risk patients on active surveillance who receive confirmation testing within 24 months of diagnosis	Made minor wording changes to clarify focus on biopsy: Percentage of newly diagnosed low risk patients on active surveillance who receive confirmation biopsy within 24 months of diagnosis
		Denominator: Patients aged 30-75 with new diagnosis of low risk prostate cancer who are on active surveillance	Per codes to indicate the patient is NOT on active surveillance: added one CPT code and 2 HCPCS codes
		Exceptions: Treatment for prostate cancer within 12 months post-diagnosis	Per codes to indicate the patient is NOT on active surveillance: added one CPT code and 2 HCPCS codes
MUSIC4	Prostate Cancer: Active Surveillance/Watchful Waiting for Newly Diagnosed Low Risk Prostate Cancer Patients	Numerator: Patients on active surveillance or watchful waiting	Per codes to indicate the patient is NOT on active surveillance or watchful waiting: added one CPT code and 2 HCPCS codes